Novacyt

ALNOV · PA · Healthcare / Medical Devices

0.45EUR+0.02 (+4.65%)

Price History

Full chart

Market Stats

Previous Close0.43

Open0.44

Day Range0.4305 – 0.455

52-Week Range0.29 – 1.04

Volume156.80K

Market Cap32.63M

P/E (TTM)0.00

Forward P/E0.00

EPS-0.36

Dividend Yield0.00%

Beta1.12

50-Day Avg0.489

200-Day Avg0.4405

About

Novacyt S.A., together with its subsidiaries, develops, manufactures, and commercializes a range of molecular assays and instrumentation to deliver workflows and services for human health, animal health, and environmental sectors. It operates through Yourgene Health and Primer Design segments. The Yourgene Health segment delivers molecular diagnostic and screening solutions, across reproductive health and precision medicine. The Primer Design segment designs, manufactures, and markets molecular real-time qPCR testing devices and reagents in the areas of infectious diseases. It operates in the United Kingdom, France, Europe, the United States, the Asia Pacific, the Middle East, and Africa. The company was incorporated in 2006 and is based in Le Vésinet, France.

Company Details

SectorHealthcare
IndustryMedical Devices
CEOMr. Lyn Dafydd Rees
Employees216
Headquarters131 Boulevard Carnot, Le Vésinet, France, 78110, France
Websitehttps://www.novacyt.com

Leadership

Mr. Lyn Dafydd ReesCEO & Executive Director · b. 1973
Mr. Steve GibsonCFO, Company Secretary & Director
Mr. Peter CoyneChief Operations Officer
Ms. Wendy CoxDirector of HR

Financials

Income Statement

Currency: GBP	2008-12-31	2009-12-31	2010-12-31	2011-12-31	2012-12-31	2013-12-31	2014-12-31	2015-12-31	2016-12-31	2017-12-31	2018-12-31	2019-12-31	2020-12-31	2021-12-31	2022-12-31	2023-12-31	2024-12-31	2025-12-31
Total Revenue	508.00K	1.03M	1.27M	762.83K	901.99K	1.15M	4.53M	8.88M	11.07M	12.75M	13.72M	13.07M	277.20M	92.60M	21.04M	11.58M	19.63M	20.40M
Growth (%)	-	+102.05%	+23.49%	-39.82%	+18.24%	+27.94%	+292.20%	+96.22%	+24.62%	+15.20%	+7.62%	-4.73%	+2020.69%	-66.59%	-77.28%	-44.97%	+69.53%	+3.94%
Cost of Revenue	669.00K	1.93M	1.75M	707.40K	737.26K	600.00K	2.74M	4.92M	5.84M	5.58M	6.15M	4.13M	66.08M	29.11M	15.29M	7.85M	-12.44M	12.52M
Gross Profit	-	-903.09K	-481.66K	55.43K	164.73K	554.00K	1.78M	4.11M	5.91M	7.14M	7.58M	7.34M	211.13M	63.50M	5.75M	3.73M	32.07M	7.89M
Gross Margin	-	-87.98%	-38.00%	7.27%	18.26%	48.01%	39.44%	46.32%	53.36%	56.03%	55.21%	56.15%	76.16%	68.57%	27.31%	32.21%	163.39%	38.65%
Operating Expense	-	45.63K	58.09K	627.74K	633.19K	1.89M	4.33M	7.26M	8.91M	7.27M	7.88M	8.50M	43.69M	67.41M	29.14M	33.25M	69.42M	21.06M
Operating Income	-	-948.72K	-539.75K	-572.31K	-468.46K	-1.33M	-2.54M	-3.15M	-3.00M	-122.00K	-308.00K	-1.16M	167.44M	-3.92M	-23.39M	-29.52M	-37.34M	-13.18M
Operating Margin	-	-92.43%	-42.58%	-75.02%	-51.94%	-115.59%	-56.21%	-35.48%	-27.13%	-0.96%	-2.24%	-8.90%	60.40%	-4.23%	-111.18%	-254.91%	-190.23%	-64.58%
EBITDA	-	-806.31K	-422.41K	-597.97K	-291.80K	-1.15M	-2.36M	-2.84M	-2.16M	-1.49M	-255.00K	280.39K	168.24M	38.53M	-15.47M	-18.24M	-11.27M	-8.21M
EBITDA Margin	-	-78.55%	-33.33%	-78.39%	-32.35%	-99.25%	-52.05%	-32.01%	-19.54%	-11.65%	-1.86%	2.15%	60.69%	41.60%	-73.55%	-157.55%	-57.41%	-40.25%
Net Income	-	-590.22K	-591.31K	-571.58K	-455.22K	-831.81K	-3.91M	-10.26M	-4.87M	-4.83M	-4.74M	-6.55M	132.42M	-9.73M	-25.73M	-28.29M	-41.76M	-23.31M
Net Income Margin	-	-57.50%	-46.65%	-74.93%	-50.47%	-72.08%	-86.43%	-115.57%	-43.98%	-37.89%	-34.53%	-50.13%	47.77%	-10.51%	-122.29%	-244.34%	-212.73%	-114.25%
R&D	-	-	-	-	-	438.00K	467.00K	433.93K	814.36K	626.00K	406.00K	385.30K	1.63M	4.82M	5.05M	3.23M	2.77M	4.19M
R&D as % of Total Revenue	-	-	-	-	-	37.95%	10.32%	4.89%	7.36%	4.91%	2.96%	2.95%	0.59%	5.20%	23.99%	27.88%	14.10%	20.53%
Interest Expense	0	81.25K	123.84K	122.93K	85.07K	837.4	49.00K	1.04M	1.25M	1.26M	682.00K	1.47M	2.25M	120.00K	471.84K	2.44M	5.12M	679.48K
Interest Expense % of Total Revenue	0.00%	7.92%	9.77%	16.12%	9.43%	0.07%	1.08%	11.68%	11.33%	9.91%	4.97%	11.24%	0.81%	0.13%	2.24%	21.04%	26.09%	3.33%

Balance Sheet

Currency: GBP	2008-12-31	2009-12-31	2010-12-31	2011-12-31	2012-12-31	2013-12-31	2014-12-31	2015-12-31	2016-12-31	2017-12-31	2018-12-31	2019-12-31	2020-12-31	2021-12-31	2022-12-31	2023-12-31	2024-12-31	2025-12-31
Total Assets	1.65M	1.92M	1.90M	1.26M	3.30M	2.66M	20.77M	12.62M	25.95M	30.20M	29.31M	26.54M	234.28M	183.70M	140.90M	133.81M	70.63M	40.28M
Total Liabilities	1.91M	2.57M	2.75M	2.00M	1.96M	862.25K	6.37M	6.57M	10.80M	8.09M	11.16M	14.07M	83.57M	41.88M	25.68M	46.57M	22.75M	16.94M
Total Equity	-	-654.03K	-845.81K	-892.12K	1.64M	2.25M	20.27M	7.77M	15.15M	24.91M	18.15M	12.47M	150.71M	141.81M	115.22M	87.24M	47.88M	23.34M
Cash	14.00K	119.55K	109.33K	32.09K	463.48K	840.00K	1.82M	526.33K	2.43M	4.34M	1.02M	1.54M	91.77M	101.75M	86.97M	44.05M	30.45M	19.13M
Total Debt	-	1.99M	2.10M	856.31K	505.04K	162.23K	1.03M	3.37M	5.35M	3.46M	5.23M	10.09M	2.77M	1.87M	872.00K	13.70M	11.88M	10.44M
Net Debt	-	1.87M	1.99M	824.22K	41.55K	-677.77K	-790.22K	2.84M	2.90M	-401.26K	3.82M	7.81M	-89.39M	-99.88M	-86.10M	-30.35M	-18.57M	-8.69M

Cash Flow

Currency: GBP	2009-12-31	2010-12-31	2011-12-31	2012-12-31	2013-12-31	2014-12-31	2015-12-31	2016-12-31	2017-12-31	2018-12-31	2019-12-31	2020-12-31	2021-12-31	2022-12-31	2023-12-31	2024-12-31	2025-12-31
Operating Cash Flow	-705.19K	33.77K	-576.20K	-225.28K	-1.07M	-678.92K	-3.95M	-2.18M	-4.12M	-1.12M	-916.70K	102.98M	15.69M	-13.73M	-24.99M	-8.49M	-8.76M
Investing Cash Flow	-238.91K	-158.14K	-200.19K	-575.85K	-369.52K	-748.45K	-800.70K	-6.28M	-2.51M	-2.45M	-1.11M	-7.96M	-5.03M	-577.00K	-13.94M	-1.86M	-811.91K
Financing Cash Flow	816.10K	113.47K	699.12K	2.43M	768.09K	2.34M	4.24M	9.54M	7.98M	689.64K	2.52M	-5.04M	-599.00K	-516.00K	-3.97M	-1.84M	-1.99M
Capital Expenditure	275.62K	158.14K	167.12K	471.26K	309.44K	487.51K	611.77K	467.12K	868.21K	616.62K	287.06K	1.18M	4.10M	416.00K	671.00K	1.86M	273.01K
Free Cash Flow	-980.82K	-124.37K	-648.12K	-655.63K	-1.21M	-1.17M	-4.56M	-2.65M	-4.99M	-1.74M	-1.20M	101.80M	11.59M	-14.14M	-25.66M	-11.01M	-9.03M
Dividends Paid	-	-	-	-	-	11.72K	2.08M	-	0	-	-	-	-	-	-	-	-
FCF to OCF	139.08%	-368.27%	112.48%	291.03%	112.61%	171.81%	115.51%	121.41%	121.05%	154.90%	131.31%	98.85%	73.87%	103.03%	102.68%	129.68%	103.12%
Dividend Paid to FCF	-	-	-	-	-	-1.00%	-45.70%	-	0.00%	-	-	-	-	-	-	-	-

Earnings

Report Date	May 18, 2016	Oct 27, 2016	May 5, 2017	Aug 16, 2017	Apr 26, 2018	Sep 26, 2018	Nov 28, 2018	Apr 30, 2019	Sep 26, 2019	Nov 27, 2019	May 14, 2020	Sep 17, 2020	Dec 2, 2020	Apr 9, 2021	Sep 27, 2021	Dec 1, 2021	Apr 28, 2022	Sep 29, 2022	Nov 30, 2022	Apr 27, 2023	Sep 28, 2023	Nov 29, 2023	May 29, 2024	Sep 26, 2024	Nov 27, 2024	Apr 30, 2025	Sep 30, 2025	Dec 3, 2025
EPS Estimate	-0.36	0.00	0.06	-0.09	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
EPS Actual	-1.77	-0.25	-0.22	-0.09	-0.13	-0.13	0.00	-0.13	-0.03	0.00	-0.05	0.61	0.00	2.33	-0.22	0.00	0.04	0.00	0.00	0.00	0.00	0.00	0.00	-0.25	0.00	0.00	0.00	0.00
Surprise	-391.67%	-	-466.67%	0.00%	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Timing	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	Pre-market	-	After-hours	Pre-market	-	-	-	-	-	-	-

Key Statistics & Ratios

Market Cap32.63M

Enterprise Value25.81M

Trailing P/E0.00

Forward P/E0.00

PEG Ratio0.00

Price / Sales1.50

Price / Book1.32

EPS-0.36

Book Value0.3039

Revenue (TTM)21.79M

Gross Profit (TTM)11.45M

EBITDA3.73M

Profit Margin-102.49%

Operating Margin-44.17%

Return on Equity-75.24%

Return on Assets-12.92%

Shares Outstanding72.50M

Shares Float72.21M

Beta1.12

Dividend Yield0.00%

Dividend Rate0.00

Payout Ratio0.00%